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Recent findings have brought optimism that development of a successful human immunodeficiency virus
type-1 (HIV-1) vaccine lies within reach. Studies of early events in HIV-1 infection have revealed when and
where HIV-1 is potentially vulnerable to vaccine-targeted immune responses. With technical advances in
human antibody production, clues about how antibodies recognize HIV-1 envelope proteins have uncovered
new targets for immunogen design. A recent vaccine regimen has shown modest efficacy against HIV-1
acquisition. However, inducing long-term T and B cell memory and coping with HIV-1 diversity remain
high priorities. Mediators of innate immunity may play pivotal roles in blocking infection and shaping immu-
nity; vaccine strategies to capture these activities are under investigation. Challenges remain in integrating
basic, preclinical and clinical research to improve predictions of types of immunity associated with vaccine
efficacy, to apply these insights to immunogen design, and to accelerate evaluation of vaccine efficacy in
persons at-risk for infection.Human Immunodeficiency Virus Type-1: The Epidemic
and the Need for a Vaccine
Since 1981, more than 25 million people have died of Acquired
Immune Deficiency Syndrome (AIDS). As of 2009, UNAIDS esti-
mates that 33.4 million now live with human immunodeficiency
virus type-1 (HIV-1) infection, and 2 million become newly diag-
nosed with HIV-1 each year. Sub-Saharan Africa continues to
bear the major burden with 22 million HIV-infected persons.
Anti-retroviral therapy (ART) can suppress viral replication,
increasing life expectancy among those infected, but cannot
cure infection; with rare exceptions, HIV-1 infection left
untreated leads to death. Sustaining affordable ART coverage
in resource-poor, HIV-1 endemic regions is a daunting global
health problem. A safe, efficacious vaccine affords the best
long-term solution to ending the HIV-1 epidemic.
Several modalities can reduce HIV-1 infection rates in persons
at risk for exposure, including screening of donor blood prod-
ucts, risk reduction counseling, behavioral modifications,
condom usage, and male circumcision. Preexposure or postex-
posure ART prophylaxis may reduce susceptibility, with one
recent trial demonstrating 39% efficacy in lowering HIV-1 inci-
dence rates among South African women using a tenofovir
vaginal gel before and after sexual activities (Abdool Karim
et al., 2010). Treatment of infected persons canmarkedly reduce
transmission risk frommother to child, in exposed persons living
in high-seroprevalence communities, and between heterosexual
discordant couples. Together, these interventions can slow the
epidemic and complement partially effective vaccine regimens.
However, a highly efficacious preventive vaccine is key to gener-
ating long-term immunological memory to sustain protection
against HIV-1 infection.
A fundamental barrier to HIV-1 vaccine development lies with
the unique properties of the virus: its entry is predominantly
through mucosal surfaces, its preferred target is human CD4+542 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.T cells, and it rapidly establishes a persistent reservoir of latently
infected cells. Properties of transmitted (founder) viruses from
mucosal transmission indicate that in 70%–80% of cases, a
single virus or virus-infected cell establishes productive clinical
infection (Keele et al., 2008). Such viruses typically exhibit C-C
chemokine receptor type 5 (CCR5)-dependence, mask func-
tional envelope trimers needed to trigger antibody neutralization,
and undergo rapid mutation as productive infection ensues
(Goonetilleke et al., 2009; Keele et al., 2008). Taken together,
these viral properties have direct implications in defining specific
host innate and adaptive immune pathways that can efficiently
defend against HIV-1 entry and productive infection, and in
optimizing ways to elicit these responses at the site of exposure.
As a result of genetic sequence variability created by its error-
prone reverse transcriptase as well as mutations selected by
host immune pressure, HIV-1 has evolved into multiple subtypes
or clades together with circulating recombinant forms (collected
at http://www.hiv.lanl.gov). Because of this global diversity (up to
35% in envelope gp120), it may impossible to design a single
vaccine candidate that can induce potent effector immunity to
multiple key antigenic determinants among worldwide circu-
lating, infecting HIV-1 strains.
State of the HIV-1 Vaccine Field
After the identification of HIV-1 as the etiologic agent of AIDS,
nonhuman primate models were established to examine vaccine
effects after experimental retroviral challenge; the utility and limi-
tations of these models in predicting vaccine efficacy have been
well described (Sodora et al., 2009). Since 1987, more than
30 candidate HIV-1 vaccines whose prototypes have elicited
varying degrees of protective responses in nonhuman primate
models have advanced to human clinical trials, alone or in com-
binations (Mascola and Montefiori, 2010; Ross et al., 2010).
These include replication-competent or incompetent viral
Table 1. Overview of Candidate HIV-1 Vaccine Regimen Prototypes Evaluated in Clinical Trials and Summary of Findings
Vaccine Immunogenicity Extended Evaluation
Recombinant Env gp120 Proteins with Adjuvants
d Alum, MF-59
d QS21, MPL, MDP, MTP-PE,
liposome/lipid A, AS02a
d CD4-binding Abs, mediate ADCC,
Tier 1 viruses neutralized but not
broadly reactive (McElrath et al., 2000)
d CD4 lymphoproliferation
(McElrath et al., 2000)
d some unique adjuvants enhance titers up to
3-fold with dose-sparing effects, increased
local and systemic
reactogenicity (Evans et al., 2001;
McElrath, 1995)
d phase III efficacy trials: VAX003 in
Thailand (AIDSVAX B/E plus alum) and
VAX004 in North America and Europe
(AIDSVAX B/B plus alum), showed no
efficacy against HIV-1 acquisition or post-
infection viremia (Flynn et al., 2005; Pitisut-
tithum et al., 2006)
d new adjuvant Phase I studies planned
HIV-1 DNA Plasmid
d naked
d with CRL005, IL-15, IL-12
d delivered by electroporation
d weakly immunogenic alone, CD4+ T cells
more commonly elicited than CD8+ T cells
but CD8+ T cells enhanced with vector
boost (Catanzaro et al., 2007)
d no significant enhancement with adjuvants/
cytokines detected (Asmuth et al., 2010)
d electroporation enhances immunogenicity
(Vasan et al., 2009)
d DNA in common use as a prime combined
with a vector boost in phase I-II studies
d additional studies in progress to evaluate
combinations with cytokines and
electroporation
Viral Vectors
d Pox viruses:
o vaccinia: live replicating, MVA, NYVAC
o canarypox
o fowlpox
d adenovirus
o serotype 5, 35, 26
d VEE
d adeno-associated virus
d Ad5 vectors induce the highest CD8+ T cell
response rates and magnitude (CD8 > CD4)
of all vectors tested
(McElrath et al., 2008)
d previous vector immunity associated with
reduced T cell immunogenicity (McElrath
et al., 2008)
d first generation VEE, AAV candidates
weakly immunogenic
d phase IIb trials: Step trial in the
Americas and Phambili trial in the
Republic of South Africa (Ad5-HIV-1
trivalent vaccine) (Buchbinder et al., 2008;
Gray et al., 2010): replication-incompetent
Ad5 vector encoding HIV-1 gag, pol and nef
genes in three doses showed no efficacy
against HIV-1 acquisition or post-infection
viremia
d NYVAC, Ad26 and MVA mosaic vaccines
planned for phase I-II studies
Prime-Boost Regimens
d vaccinia + gp160
d canarypox (ALVAC) + gp120/alum
or gp120/MF59
d DNA + Ad5 (VRC)
d DNA + MVA (GeoVax, SAAVI)
d DNA + NYVAC
d DNA + gp140
d MVA + fowlpox (GeoVax)
d HIVAC-1e + gp160/alum the first regimen
shown to induce neutralizing Abs and CD8+
CTL (Cooney et al., 1993)
d DNA + Ad5 induce both CD4+ and CD8+
multifunctional T cells (Kibuuka et al., 2010)
d ALVAC + gp120 induce CD4+ > CD8+
responses, tier 1 neutralizing Abs
d DNA + NYVAC or MVA induce
multifunctional CD4+ > CD8+ T cells
(Harari et al., 2008)
d heterologous pox vector regimen elicits
greater T cell response rates than repeated
MVA
d phase III efficacy trial: RV144 trial
in Thailand (ALVAC-HIV vCP1521 +
AIDSVAX gp120 B/E) (Rerks-Ngarm et al.,
2009): canarypox vector encoding HIV-1
gag, env and protease (4 doses) plus gp120
subunit boost (2 doses) showed 31%
efficacy against HIV-1 acquisition in
predominantly heterosexual men and
women
d DNA + Ad5 (VRC) in expanded phase II
testing
d Ongoing phase II (DNA + MVA),
additional studies planned
(DNA + NYVAC)
See comprehensive summary in Ross et al. (2010). Phase IIb and III trials are highlighted in bold.
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containing HIV-1 gene inserts; HIV-1 viral-like particles; HIV-1
DNA plasmids; and soluble HIV-1 proteins and peptides, with
or without adjuvant formulations (Table 1). Prime-boost heterol-ogous regimens have been employed to enhance the potency
and breadth of antibody and T cell responses.
Those candidate regimens that have been extended to large-
scale international phase IIb or III studies (highlighted in Table 1)Immunity 33, October 29, 2010 ª2010 Elsevier Inc. 543
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vaccines, AIDSVAX B/E with alum (Vax003 trial) (Pitisuttithum
et al., 2006) and AIDSVAX B/B with alum (Vax004 trial) (Flynn
et al., 2005); the replication-incompetent adenovirus serotype
5 (Ad5) vectored HIV-1 trivalent vaccine (Step and Phambili trials)
(Buchbinder et al., 2008; Gray et al., 2010); and the canarypox
ALVAC-HIV vCP1521 plus AIDSVAX gp120 clades B and E
(RV144 trial) (Rerks-Ngarm et al., 2009). Only the RV144 trial,
evaluating a recombinant canarypox-HIV vector prime and
recombinant HIV-1 envelope gp120 subunit protein plus alum
boost in Thailand, showed low-level efficacy (31%) in reducing
HIV-1 infection rates (Rerks-Ngarm et al., 2009). No regimen
has induced vaccine responses associated with set-point viral
load reduction after acute infection or other sustained clinical
parameters related to improved outcomes.
Apart from safety, the overriding principles guiding HIV
vaccine development have been the predicted ability of the
immunogen to induce either HIV-1 neutralizing antibodies or
HIV-1-specific CD8+ T cells, or both. Although there have been
strong proponents of either antibodies or T cells alone as the
most effective strategy, taking into account the correlates of
immune protection against other viral pathogens as well as
understanding the immune components that control HIV-1
in vivo, the consensus view now is that a highly effective vaccine
will need to elicit coordinated B cell, CD4+ and CD8+ T cell
responses. Moreover, it is anticipated that specific adjuvants
and vectors can trigger innate immune signaling pathways that
can improve the potency and quality of adaptive immunity.
Recent studies in acute infection have emphasized the rapidly
destructive nature of HIV-1, and the need for protective immune
responses to be present concurrently with, if not before, HIV-1
transmission (Haase, 2010; McMichael et al., 2010).
Innate Mechanisms Altering HIV-1 Vaccine Immunity
and Protection
Although innate immune mechanisms contribute to HIV-1
control (Alter et al., 2007), it remains unclear whether recapitu-
lating these responses with a vaccine will enhance protection
against HIV-1 acquisition. Understanding how innate cells
capture and present HIV-1 antigens through vector delivery
and adjuvant formulations is receiving growing interest, with
investigations ongoing to identify chemoattractants that recruit
inflammatory cells at the vaccination site, promote dendritic
cell (DC) activation andmaturation, optimize antigen intracellular
presentation or cross-presentation, and delineate innate cell
populations and signaling pathways for selectively inducing
long-term B versus T cell responses.
Natural killer (NK) cells provide the first wave of attack against
viral infection, mediating antibody-dependent cell-mediated
cytotoxicity (ADCC) and antibody-dependent cell-mediated
viral inhibition (ADCVI) and secreting antiviral cytokines and
chemokines. HIV-1-infected subjects expressing NK receptors
KIR3DS1 and KIR3DL1 in conjunction with HLA-B Bw480I
have slower HIV-1 disease progression, and expansions of
these NK cell populations have been observed in acute infection
(Alter et al., 2009). NK cells can also contribute to recall
responses and thus may serve as memory cells in some viral
infections (Sun et al., 2010). Efforts are underway to investigate
the contribution of NK cells to the low-level protective effect544 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.observed in the RV144 trial; conceivably, NK cells bound to
HIV-1 envelope (Env) antibodies may have mediated ADCC.
A variety of host genetic determinants impacting HIV-1 core-
ceptor interactions, replication, and immune responsiveness
can contribute to altered HIV-1 susceptibility or disease progres-
sion that may occur independent of, or contribute to, vaccine
effects (Fellay et al., 2007; O’Brien and Nelson, 2004). To date,
two genetic studies have shown relevance to HIV vaccine effi-
cacy— polymorphisms at gene loci encoding FcgRIIa and
FcgRIIIa influenced the degree to which ADCVI responses to
gp120 predicted rate of infection in the Vax004 trial (Forthal
et al., 2007) and the presence of certain protective or nonprotec-
tive HLA-B alleles was associated with the magnitude of
Gag-specific T cell responses in male vaccinees in the Step trial
(Fellay et al., 2009). The extent to which these factors alter
immune pathways and HIV-1 susceptibility should be taken
into consideration in the evaluation of future HIV-1 vaccine
candidates.
Role of Envelope Antibodies in HIV-1 Prevention
Neutralizing antibodies (nAbs) are correlates of protective immu-
nity of all FDA-approved vaccines against infectious agents.
Although both infection and HIV-1 envelope immunization can
induce nAbs, those antibodies that broadly neutralize a wide
range of HIV-1 strains are neither common nor of long duration.
However, passive administration of rare human anti-Env mono-
clonal broadly neutralizing antibodies (bnAbs) with titers that
can be achieved by immunization can protect against simian-
human immunodeficiency chimeric virus (SHIV, containing
some HIV-1 genes, including env, tat, and rev, on a simian
immunodeficiency virus [SIV] backbone) challenge in rhesus
macaques (Hessell et al., 2007; Hessell et al., 2009a; Hessell
et al., 2009b; Mascola, 2002; Mascola and Montefiori, 2010;
Montefiori and Mascola, 2009). Thus, a major goal of HIV-1
vaccine development is to design immunogens capable of
inducing antibodies that can broadly neutralize HIV-1 (Mascola
and Montefiori, 2010; Stamatatos et al., 2009).
One major obstacle in HIV-1 vaccine development is con-
structing Env immunogens with immunogenic broadly neutral-
izing epitopes. First, conserved Env epitopes targeted by bnAbs
are poorly immunogenic because they either are masked by
carbohydrates (Binley et al., 2010; Wei et al., 2003), appear
transiently (Frey et al., 2008), are sterically hindered (Labrijn
et al., 2003; Schief et al., 2009), or must overcome entropy for
antibody binding (Kwong et al., 2002). Second, Env glycans
are antigenically similar to host carbohydrates (Astronomo
et al., 2008). Third, some Env protein epitopes have homologies
with self proteins, and when immunogenic, induce polyreactive
antibodies that may be subjected to tolerance mechanisms
(Haynes et al., 2005; Verkoczy et al., 2010). By contrast, easily
induced HIV-1 Env antibodies typically recognize type-specific
neutralizing epitopes located on variable loops (Davis et al.,
2009; Moore et al., 2009) or recognize dominant non-neutral-
izing, conserved epitopes in gp120 (Palker et al., 1987) or gp41
(Gnann et al., 1987). Many of these nonneutralizing dominant
epitopes are present only on structurally nonnative Env. Finally,
even when antibodies can neutralize the infecting strain, their
effect is transient because escape mutations are selected
(Richman et al., 2003; Wei et al., 2003). Thus, immunization of
Table 2. Characteristics of Human Antibodies Capable of Broadly Neutralizing HIV-1
Antibody Specificity Isotype HCDR3 length VH, VK/VL Family VH% mutated Polyreactivity
2F5 gp41 MPER IgG3 24 2-5, K1-13 12.4% Yes
4E10 gp41 MPER IgG3 20 1-69, K3-20 6.3% Yes
2G12 Env glycans IgG1 16 3-21, K1-5 19.6% Reacts with fungal carbohydrates
1b12 CD4 binding site IgG1 20 1-3, K3-20 11.8% Yes
VRC01 CD4 binding site IgG1 14 1-2, K3D-15 31.2% No
HJ16 Core/CD4 binding site/DMR IgG1 21 3-3, K4-1 13.7% N/A
PG9 Quaternary gp120 (V2, V3) IgG1 30 3-33, L2-14 12.8% No
PG16 Quaternary gp120 (V2, V3) IgG1 30 3-33, L2-14 11.9% No
N/A, not available. Data on HJ16 courtesy of personal communication from D. Corti and A. Lanzavecchia.
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trimers has failed to induce antibodies recognizing broadly
neutralizing envelope epitopes. Rather, induced antibodies
neutralize the strain represented in the immunogen sequence
or easily neutralized strains (termed Tier 1 strains); only sporadic
and weak neutralization is observed for difficult to neutralize
(Tier 2 and Tier 3 strains) primary HIV-1 isolates that are
representative of clinically relevant field isolates (reviewed in
Gilbert et al., 2010; Mascola and Montefiori, 2010; and refer-
ences therein).
Specificities of Broadly Neutralizing Antibodies
Approximately 20% of chronically HIV-1 infected subjects have
of nAbs that neutralize multiple HIV-1 strains, and 2%–4% of
chronically infected subjects have serum antibodies that broadly
neutralize most HIV-1 strains tested (Simek et al., 2009). Even
though these subjects can make bnAbs, they are not made until
months to years after infection. Thus, bnAbs that develop in the
context of chronic HIV-1 infection do not protect from disease
progression (Euler et al., 2010).
Broad reactivities can be explained either by many different
specificities that contribute to breadth (Scheid et al., 2009), or
by only one or a few antibody specificities that are responsible
for breadth (Walker et al., 2010; Wu et al., 2010). An important
development of the past year has been the application of re-
combinant human monoclonal antibody (mAb) isolation and
cloning to HIV-1 vaccine development (Hicar et al., 2010; Liao
et al., 2009; Scheid et al., 2009; Walker et al., 2009; Wu et al.,
2010). Table 2 summarizes the specificities of representative
types of bnAbs and their targets, and Figure 1 shows a structural
model of HIV-1 Env trimer and locations of conserved nAb
epitopes. The specificities of broad neutralizing antibodies can
be grouped into four categories: CD4 binding site; gp41
membrane proximal external region (MPER); quarternary V2,
V3 loop; and carbohydrate.
The prototype gp120 mAb, 1b12, binds to gp120 at its CD4
binding site, surrounded and protected by N-linked glycans
(reviewed in Schief et al., 2009). A recent antibody specificity,
designated CD4bs/DMR/core, binds near the CD4 binding site,
depends on gp120 amino acids D474, M475, and R476 for reac-
tivity, and can have considerable breadth (Pietzsch et al., 2010).
Wu and colleagues designed a resurfaced stabilized gp120 core
to mimic the CD4 binding site where bnAbs but not weak or non-
neutralizing antibodies bind. Using this resurfaced core as afluorescent-labeled probe to capture antigen-specific memory
B cells, they isolated a CD4 binding site mAb, VRC01, which
neutralized 91% of tested primary isolate Env pseudoviruses
and exhibited the broadest neutralization activities of any anti-
body isolated to date (Wu et al., 2010). Structural analyses of
the CD4 binding site bound with mAbs 1b12 (neutralizing),
F105 (nonneutralizing), and VRC01 (very broadly neutralizing)
revealed the narrow site to which these antibodies must bind
(reviewed in Schief et al., 2009; Zhou et al., 2010).
Two prototype membrane-proximal external region (MPER)
gp41 nAbs are 2F5 and 4E10. 2F5 binds to a core target at
ELDKWA in the heptad repeat-2 region of gp41, whereas 4E10
binds to the NWFDIT sequence at the insertion of the gp41
stalk into the virion lipid membrane (Cardoso et al., 2005;
Ofek et al., 2004). These antibodies bind to both lipid-MPER
peptide complexes and to HIV virions (Alam et al., 2009) in
a two-step conformation change model wherein they bind first
to virion lipids, then surf the viral membrane while awaiting tran-
sient exposure of their neutralizing epitopes during fusion with
a target cell.
Antibodies directed to a dominant linear epitope at the tip
of the gp120 V3 loop are commonly made. Although potent
against Tier 1 HIV-1 strains and T cell line adapted (easy to
neutralize) HIV-1, most V3 loop antibodies cannot neutralize
either Tier 2 and 3 primary strains or transmitted founder viruses
(Davis et al., 2009). Zolla-Pazner isolated V3-specific human
mAbs with a degree of breadth from chronically infected HIV-1
subjects and identified an antibody, 2909, that recognizes
a strain-specific quaternary epitope involving gp120 V2 and V3
loops in the context of Env trimer (reviewed in Zolla-Pazner
and Cardozo, 2010). Two new bnAbs, PG9 and PG16, also
recognize quaternary gp120 V2 and V3 region epitopes, is
dependent on V2 N-linked glycosylation sites, and neutralize
80% of HIV-1 primary isolates (Pancera et al., 2010; Walker
et al., 2009).
The 2G12 Env carbohydrate mAb is unusual in two aspects.
First, it is the only purely glycan-targeted bnAb isolated thus
far. Second, it has a unique domain-swap structure such that
its Fab region is composed of a heavy and light chain from two
members of a 2G12 dimer (Calarese et al., 2003; Scanlan
et al., 2002). The glycans on gp120 are the result of host
cell posttranslational modifying glycosidases, and therefore
resemble host carbohydrates (Scanlan et al., 2002), with
oligomannose residues comprising most glycans on CD4+Immunity 33, October 29, 2010 ª2010 Elsevier Inc. 545
Figure 1. Unliganded Model of the HIV-1
Envelope Trimer
All glycans on gp160 are shown. Glycans are light
blue and white, core gp120 is red, 2G12 epitopes
are in white (arrow), B12 and VRC01 epitopes
are yellow (arrow), and the location of the quarter-
nary epitope involving V2 and V3 loops of mAbs
PG9 and PG16 is indicated. Image courtesy
of W. Schief, University of Washington, Seattle,
WA, adapted with permission from Schief et al.
(2009).
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nized by 2G12 comprise a unique conformational epitope of
oligomannose glycans that is nonimmunogenic (Astronomo
et al., 2008). Thus, the HIV-1 envelope has at least four
conserved regions, each with overlapping epitopes that can be
targets for broad neutralizing antibodies. Many recombinant
envelopes are antigenic and bind broad neutralizing antibodies,
but for the reasons outlined below, recombinant envelopes are
not immunogenic for these types of antibodies.
Characteristics of Broad Neutralizing Antibodies
HIV-1 bnAbs have unusual characteristics that include either long
heavy chain complementarity determining region 3 (HCDR3),
polyreactivity, or high levels of mutations (Table 2). Compelling
evidence exists for immunoregulatory mechanisms that control
production of B cells with immunoglobulin genes containing
long HCDR3 regions (Meffre et al., 2001; Shiokawa et al., 1999).
B cells with long hydrophobic HCDR3s appear to be eliminated
at thenaiveBcell stage (Meffreet al., 2001;Shiokawaet al., 1999).
Polyreactivity is a normal component of the antibody reper-
toire; in the preselection bone marrow repertoire, up to 40% of
antibodies are polyreactive, whereas in the postselection (post-
tolerance) repertoire only 15%–20% of antibodies are
polyreactive (Wardemann et al., 2003). In transgenic mice, poly-
reactive double-stranded DNA autoantibodies are either deleted
in bone marrow or modified in the periphery by tolerance mech-
anisms (Chen et al., 1995). By contrast, the immune regulatory
mechanisms for somatic hypermutation levels are unclear.
Nonetheless, the mean number of mutations in a secondary
immune response such as against influenza is  5%, in contrast
to the generally higher number of mutations in HIV-1 broad
neutralizing antibodies (Table 2).546 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.Many rare bnAbs are polyreactive and
react with a number of host and other
non-Env molecules, including host and
virion lipids (Haynes et al., 2005). Approx-
imately 70% of recombinant memory
anti-Env B cells derived from rare sub-
jects with broad neutralizing antibodies
are polyreactive and react with host and
other non-HIV antigens (Mouquet et al.,
2010).
Polyreactivity of HIV-1 antibodies can
be functionally important. Lipid polyreac-
tivity of gp41 nAbs is required for neutral-
ization (Alam et al., 2009). An antibody
binding to the CD4-inducible CCR5binding site on gp120 has been found that also uses adjacent
bound CD4 as a part of the CD4i epitope (Diskin et al., 2010).
Because of the low number of Env trimer spikes on the HIV-1
virion, the likelihood of bivalent antibody-virion binding in the
absence of antibody polyreactivity is small (Klein and Bjorkman,
2010). Nussenzweig and Mouquet have demonstrated that
induction of polyreactive antibodies by HIV-1 facilitates Env
antibody bivalent binding (avidity) on virions by allowing anti-
body crosslinking via Env and virion host molecules (M. Nus-
senzweig, personal communication; Mouquet et al., 2010).
Thus, the hypothesis is that the host needs to induce polyreac-
tive antibodies, in effect, to overcome HIV-1 escape from anti-
body avidity (Klein and Bjorkman, 2010). In the majority of
subjects, tolerance mechanisms would then limit expression
of high-affinity HIV-1 antibodies that could broadly neutralize
(Haynes et al., 2005). In this regard, mice that only express the
2F5 variable heavy (VH) immunoglobulin chain regulate 2F5
VH expression by both central and peripheral tolerance mecha-
nisms (Verkoczy et al., 2010).
The construction of inferred reverted unmutated ancestor
antibodies (RUAs) that are candidates for being the germline
antibodies of naive B cell precursors of bnAbs has demonstrated
that in some cases, the RUAs of bnAbs do not react with the
same epitopes as the highly mutated observed descendant
antibodies (Pancera et al., 2010; Xiao et al., 2009; Zhou et al.,
2010). Thus, induction of bnAbs may be complicated by the
need for antigens other than targets of the somatically mutated
bnAb to stimulate affinity maturation of the appropriate naive B
cell clone to recognize conserved Env regions (S.M. Alam
et al., 2010, AIDS Vaccine 2010, abstract; M. Bonsignori et al.,
2010, AIDS Vaccine 2010, abstract; Dimitrov, 2010; Xiao et al.,
2009; Zhou et al., 2010).
HIV-1 
Stratified
squamous epithelium
Columnar epithelium
Mucus layer Mucus layer
Langerhan
or dendritic cell
CD4+ T cell
Macrophage FcR-mediated
phagocytosis of virions and
ADCC of virus infected CD4+ T cells
NK cell FcR-mediated ADCC
HIV-1 intereaction with:
CD4, CCR5, α
4
β
7
5-9
10-11
4
4
3 3
2 2
1 1
HIV-1-infected cell
Figure 2. Steps in Mucosal HIV-1
Transmission Potentially Amenable
to Intervention by Vaccination
Steps are keyed to assays listed in Table S1. Anti-
bodies that score positive in in vitro assays and
protect against SHIV acquisition in in vivo passive
protection trials in nonhuman primates are candi-
dates for correlates of protective immunity in the
RV144 vaccine trial. Free virions or virions from
infected cells can be aggregated by antibodies
(1) and their movement through the mucus layer
inhibited (2). Possible sites of transmission are
female vagina and cervix (squamous epithelium),
endocervix, and rectum (columnar epithelium),
as well as male rectum (columnar epithelium and
forskin (squamous epithelium). Transcytosis
through either squamous or columnar epithelium
may be blocked by antibodies (3), as can the
transfer of DC-bound virions to CD4+ T cells (4).
Various assays measure the ability of antibody to
block CD4+ T cell and monocyte-macrophage
(not shown) infection such as inhibition of gp120
binding to a4b7 (5), pseudovirus infection inhibi-
tion (not shown) (6), PBMC infection inhibition
(not shown) (7), syncytium inhibition (not shown)
(8), and cell-to-cell infection inhibition (4 and
implied in 9). ADCVI and ADCC, as well as phagocytosis assays of opsonized virions, can measure Fc receptor-mediated anti-HIV activities. Antibody and/or
immune complexes bound to IgG FcR-bearing immune cells such as NK cells and/or monocyte macrophages can also release anti-HIV-1 chemokines and other
factors.
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in the RV144 Trial
Preliminary analyses of the canarypox ALVAC-HIV vCP1521 plus
AIDSVAX gp120 B/E (RV144) trial demonstrate that binding
antibodies to clade B and E gp120s were present in 99% of
vaccinated subjects, but titers waned 90% over 20 weeks
(J. Kim and M. De Souza, personal communication). ADCC
with HIV-1 clade B and E gp120-coated targets were detected
in 75% of vaccinees for clade B and 25% for clade E; as
with binding antibodies, titers were not stable and waned over
20 weeks (M. De Souza and J. Kim, personal communication).
Neutralizing antibodies targeted a subset of Tier 1 and 2 viruses
and were less potent than the failed Vax003 and Vax004 trials
testing gp120 without the ALVAC-HIV prime (D. Montefiori,
personal communication). Interestingly, in Vax004 (clade B
gp120MN and gp120GNE8), the vaccine induced robust gp120
binding and neutralization antibody levels to the Tier 1 strain
HIV-1 MN, but neutralization breadth for Tier 2 HIV-1 isolates
was weak and sporadic, consistent with the lack of observed
protection (Gilbert et al., 2005; Graham and Mascola, 2005).
Thus, a correlate of protection in RV144 may be a short-lived
antibody response that can neutralize or block an early phase
of the HIV-1 mucosal transmission event (Figure 2). Other
considerations for immune correlates are CD8+ and CD4+
T cell responses as well as induction of innate immune factors
such as NK cells or anti-HIV-1 chemokines (DeVico and Gallo,
2004). Because the Vax003 trial of clades B and E gp120 alone
in Thai intravenous drug users failed (Pitisuttithum et al., 2006),
the protective effect in RV144 could be due to a short-lived
immune response induced by ALVAC alone or due to synergy
of ALVAC with clades B and E gp120.
A number of in vitro assays are available to study naturally
occurring and vaccine-induced antibody effector functions,
described in Table S1 (available online) and highlighted in
Figure 2, to show where in HIV-1 transmission these functionsmay be useful. It is unclear which assays will identify protective
antibodies against HIV-1 infection in humans. A critical step to
defining correlates of protection in RV144 is to identify serum
HIV-1 antibody activity, use fluorescent-labeled gp120 Env
as a probe to sort memory B cells making such antibodies,
and then test these antibodies alone or in combination for effi-
cacy in rhesus macaque passive protection trials with CCR5-
utilizing (R5) SHIVs (Mascola, 2002). Additional R5 SHIVs are
critically needed for the nonhuman primate validation studies.
Thus, the search is on to unravel the immune responses
induced by the RV144 vaccine and to deduce the nature of
the immune responses responsible for the modest protection
seen, in order to begin to rationally improve on immunogen
design.
What Antibody Titers Are Needed to Protect?
In SHIVmodels, high titers of nAbs are needed to protect against
high-dose intravenous challenges (Mascola, 2002). However,
Hessell et al. (2009b) demonstrated that a serum titer of 1:1 in
macaques after infusion of the broad neutralizing anti-carbohy-
drate antibody 2G12 was able to protect from intravaginal
SHIV challenge. Whereas protection from high-dose intravaginal
SHIV challenge required relatively high serum titers of the CD4
binding site antibody 1b12, far lower serum titers of 1b12 can
protect against low-dose intravaginal SHIV challenge (Hessell
et al., 2009a). At low serum dilutions, 90% neutralization is
a benchmark to be attained by new vaccine candidates; the
Vax003 and Vax004 gp120 trials did not achieve this benchmark.
Therefore, if protective antibodies can be induced, the neces-
sary plasma titers will be sufficiently low so as to be attainable
by vaccination.
Easily Induced HIV-1 Envelope Antibodies
Unlike the initial CD8+ T cell response in acute HIV-1 infection
that rapidly selects for escape mutants (Cao et al., 2003;Immunity 33, October 29, 2010 ª2010 Elsevier Inc. 547
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although virion-binding, does not have neutralizing activity and
does not drive escapemutation. The first autologous neutralizing
antibody response does not develop until3months after trans-
mission (McMichael et al., 2010; Richman et al., 2003; Wei et al.,
2003). This autologous response occurs in virtually all infected
subjects, is usually specific for the transmitted (founder) virus,
and is frequently targeted to variable Env regions (Moore et al.,
2009). A major goal of HIV-1 vaccine development is to deter-
mine whether autologous nAb targets fall into groups or patterns
such that a polyvalent immunogen might be made to target
a sufficient number of founder viruses.
IgM and IgA multimeric antibodies can aggregate virions and
inhibit movement through mucous and epithelial layers (Hladik
and Hope, 2009). Others bind to Fc receptors on monocytes,
NK cells, and other hematopoietic cells to mediate killing of
infected targets via ADCC (Florese et al., 2009), inhibit HIV-1
via ADCVI (Forthal et al., 2005; Hladik and Hope, 2009), or bind
to FcRs and induce anti-HIV-1 chemokines or other antiviral
factors (DeVico andGallo, 2004). Using theCD4 binding site anti-
body 1b12 in passive protection studies in nonhuman primates,
Hessell et al. (2007) found that Fc receptor binding but not
complement binding activity was necessary for protection
against vaginal SHIV challenge. Thus for both neutralizing and
nonneutralizing anti-HIV-1 activity, antibody binding to Fc recep-
tors is important for optimal anti-HIV-1 activity.
Fc piece glycosylation is required for an antibody to bind to
Fc receptors and for mediation of effector functions (Jefferis
et al., 1995). Antibodies from HIV-1-infected subjects have
glycan profiles similar to those associated with chronic inflam-
mation (e.g., autoimmune diseases), characterized by agalacto-
sylated antibodies that are less effective at binding FcR (Moore
et al., 2005). HIV-1 elite controllers have elevated ADCC-
mediating antibody titers compared to chronic or acutely
infected subjects (Lambotte et al., 2009). ADCC and ADCVI
activity of serum antibodies, as well as transcytosis-blocking
activity in mucosal secretions, correlated with control of viral
load after vaccination with replicating recombinant adenovirus
followed by boosting with recombinant gp140 Env (Xiao et al.,
2010). Whether nonneutralizing ADCC- or ADCVI-mediating
antibodies can protect against HIV-1 acquisition remains to be
determined.
Antibodies present in mucosa but not in blood may block
HIV-1 transit across epithelial layers (Horton et al., 2009; Tudor
et al., 2009; Xiao et al., 2010). Recent studies have found
subjects with HIV-1 coreceptor CCR5 autoantibodies atmucosal
sites that are capable of downregulating CCR5 and blocking
HIV-1 infection in vitro; a subset of these subjects have mucosal
(cervical fluid or seminal plasma) anti-Env IgA that is not present
in the plasma (G.D. Tomaras et al., 2010, NIH Symposium on the
Immunology of Exposed and Uninfected Subjects, abstract).
These observations imply that multiple HIV-1 exposures can
induce host immunity and that the mucosal immune system
can respond with local antibodies that are independent of
systemic antibody responses.
Thus, it is critical to determine whether any of the above
mentioned easy-to-induce antibody types, if present before
transmission, can protect. If not, then the effort must be focused
entirely on induction of broadly neutralizing antibodies.548 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.Impact of T Cell Immunity on Natural HIV Infection:
Considerations for HIV-1 Vaccines
A central theme of HIV-1 vaccine design has been to elicit
antiviral CD8+ cytotoxic T lymphocytes (CTLs) to control HIV-1
replication and CD4+ T cells that can help induce and maintain
CD8+ and B cell responses. Extensive experimental evidence
in macaque SIV vaccine challenge models and correlative data
in human HIV-1 infection indicate that CD8+ T cells play a pivotal
role in controlling viremia during acute infection, that they exert
immune selective pressure early in infection, and that the result-
ing escape variants frequently demonstrate reduced viral fitness
(reviewed in Goulder and Watkins, 2008). Further, the associa-
tion of HIV-1 disease progression with distinct class I MHC
molecules is linked to CD8+ CTL recognition of specific HIV-1
epitopes (Dinges et al., 2010). T cell-based vaccines targeting
specific Gag epitopes have been a common approach, given
that responses to these have been associated with lower viral
loads in population-based studies (Kiepiela et al., 2007) and
conserved regions in Gag are critical for viral fitness (Troyer
et al., 2009).
The mere presence or magnitude of anti-viral CD8+ T cells
is not sufficient to control acute or chronic HIV-1 infection. More-
over, CD8+ T cell responses were induced in vaccine recipients
in the Step trial, but the response rate andmagnitude at the peak
immunogenicity time point after vaccination were not substan-
tially different in vaccinated individuals who becameHIV infected
versus matched vaccinated controls (McElrath et al., 2008). A
threshold level of T cell responses, recognizing one or more
epitopes, may be necessary to provide an efficient recall
response at the initial site of infection, and conceivably this level
was not attained in the Step trial vaccine recipients because the
vaccine regimen might have been poorly immunogenic. Thus,
more extensive antiviral functional analyses of effector and
central memory CD8+ T cells have now assumed greater impor-
tance (Table S2). Attributes ascribed to a protective phenotype
are polyfunctional cytokine production (e.g., IFN-g, TNF-a,
IL-2, and/or MIP-1b), high proliferative capacity, cytolytic poten-
tial, avidity, suppression of HIV-1 replication from infected cells,
recognition of specific epitopes restricted by protective HLA-B
alleles, long-lived central memory cells, and effector memory
cells acting rapidly at sites of mucosal exposure (Almeida
et al., 2007; Horton et al., 2006; Migueles et al., 2008; Sa´ez-
Cirio´n et al., 2007). Additionally, molecular signatures consistent
with T cell exhaustion and antiviral control will be important to
assess in vaccine studies to ensure that vaccine designs induce
memory T cells with favorable qualities (Day et al., 2006; Traut-
mann et al., 2006). The assays to measure these activities are
in place, some validated and all standardized, and outlined in
Table S2.
Although HIV-specific CD4+ T cells are induced during acute
HIV-1 infection, their helper function is compromised (Malhotra
et al., 2001). Their protective role is suggested in the less virulent
HIV-2 infection, given that maintenance of HIV-2-specific CD4+
T cells correlates with lower HIV-2 viremia (Zheng et al., 2004).
HIV-1 preferentially infects HIV-specific T cells, and thus a major
concern is that CD4+ T cells induced by vaccination can serve as
immediate HIV-1 targets, particularly because most if not all
immunogenic candidate HIV vaccines evaluated induce HIV-
specific CD4+ T cells. However, to date no evidence exists that
Immunity
ReviewCD4+ T cell activation or vaccine-induced CD4+ T cells result in
heightened HIV-1 acquisition or viremia after infection (McElrath
et al., 2008; Rerks-Ngarm et al., 2009). In SIV-challenged rhesus
macaques, data suggest that CD8+ T cell function has a greater
impact on viremia than the activation status of CD4+ target cells
(Okoye et al., 2009). However, although postulated from in vitro
studies (Benlahrech et al., 2009), whether vaccine vectors such
as Ad5 heighten activation ofmemory CD4+ T cells that preferen-
tially home to mucosal sites of HIV-1 exposure in vivo remains
unanswered. Certainly, CD4+ T cell help is critical for generating
effective, long-lived CD8+ and B cell memory responses, for
efficiently directing T cell responses to the mucosa, and for
exerting direct antiviral activities.
Of note, vaccine-induced CD4+ lymphoproliferation was the
most substantial detectable T cell response elicited by the
prime-boost regimen in the RV144 trial. Investigations are in
progress to comprehensively define the phenotypic and func-
tional properties of these T helper responses, as outlined in Table
S2. Moreover, because CD4+ T cell responses were also elicited
by gp120 plus alum vaccine regimens similar to those in the
Vax003 and Vax004 studies (McElrath et al., 2000), under-
standing the role of the canarypox vector prime in shaping the
CD4+ response may lend further insight into understanding
RV144 correlates of immune protection.
Analysis of T Cell Responses Elicited by Candidate HIV
Vaccines and Their Contribution to Protection
The development of validated assays to detect vaccine-induced
HIV-specific T cell responses has afforded the opportunity to
reliably quantify and identify epitope specificities of multiple
cytokine-secreting CD4+ and CD8+ T cells from cryopreserved
PBMC obtained from study participants worldwide. These
procedures also have permitted immunogenicity comparisons
between vaccine regimens evaluated in separate trials and,
more importantly, have provided the opportunity to conduct
case-cohort control immune correlates analyses in phase IIb-III
trials. Two validated assays, IFN-g ELISpot and intracellular
cytokine staining by flow cytometry, were applied in the evalua-
tion of vaccine-induced T cells in the Step trial (McElrath et al.,
2008). Importantly, the remarkably high response rates (90% in
male vaccinees after three immunizations), the observation that
two-thirds of responding T cells expressed two or more antiviral
cytokines, and the persistence of the CD8+ T cell responses after
1 year indicates that these measurements, although useful as
screening assays for T cell immunogenicity, did not predict
vaccine efficacy in the Step trial (McElrath et al., 2008).
Another potential explanation for why protection against HIV-1
acquisition did not occur in the Step trial is that the number and
specificity of epitopes recognized by vaccine-induced T cells
was not adequate to mount immune pressure on the infecting
viral strains. CD8+ T cells from Step vaccinees recognized a
median of one to two epitopes, in contrast to rhesus macaques
who recognize a mean of 12 epitopes from Gag, Pol, and Nef
when given similar vaccine regimens that are protective (Wilson
et al., 2009). Recent viral sequence analysis of early founder
viruses in cases receiving vaccine in contrast to those receiving
placebo prior to infection indicates that the Step vaccine did
exert substantial immune pressure (Rolland et al., 2009).
Ongoing longitudinal sequence analysis will lend insight intowhether the vaccine effect was lost soon after acute infection
and will determine the impact of protective HLA-B and KIR
alleles on postinfection viremia. The lack of efficacy in the Step
trial may be attributed to insufficient potency, antiviral activities,
and breadth of epitope recognition. As a consequence of the
findings in Step and RV144, in future trials it will be important
to evaluate more comprehensively the functional properties
and the epitope specificities of the T cells induced by vaccination
(Table S2).
Improved Vaccine Adjuvants and Delivery
Recent advances in unraveling the molecular interactions in the
innate immune signaling pathway hold promise for new adjuvant
formulations to enhance immunogenicity of HIV-1 immunogens.
Alum and MF59 adjuvants have been most widely used with
envelope gp120 immunogens in phase II or III studies (Table 1).
Other adjuvants formulated with proteins or peptides evaluated
in phase I studies include incomplete Freund’s adjuvant,
muramyl dipeptide (MDP), MTP-PE, monophosphoryl lipid A
(MPL), QS21, AS02a, liposomes with lipid-A, and lipopeptides.
Although some adjuvants generated 2- to 3-fold increased
antibody titers and CD4+ T cell responses in contrast to alum
or MF59, these effects waned with repeated dosing, and
increased local and systemic reactogenicity was observed with
some preparations (Evans et al., 2001; McElrath, 1995). Of
note, these studies were carried out when less sophisticated
immunological assays were available to define phenotypic and
functional differences in B and T cell responses. Adjuvants
(CRL1005) and cytokines (IL-12, IL-15) have also been employed
with HIV-1 DNA plasmids (Table 1), but HIV-1-specific IFN-g-
secreting T cells were not substantially enhanced by these
studies (Asmuth et al., 2010). However, preliminary findings
hold promise that delivery of DNA by electroporation may
improve immunogenicity (Vasan et al., 2009).
Increasing the pace of adjuvant development for HIV-1
vaccines is challenging. Optimizing the relative adjuvant-antigen
dose in humans is rarely feasible because of financial and time
constraints, andmust rely on predictions from preclinical studies
or empiric selection. Comparative studies are usually restricted
to products held by one sponsor. Formulation of newer adju-
vants with HIV-1 envelope immunogens to retain its antigenic
structure, particularly conformational neutralizing epitopes, is
an important requirement. Nevertheless, phase I studies are in
development to evaluate poly IC-LC (TLR3-MDA5 signaling)
and synthetic gamma-linolenic acid (TLR4 ligand) as protein
adjuvants, as well as targeting Gag protein to DCs through the
DEC-205 receptor (Carter and Reed, 2010; Longhi et al., 2009).
These approaches to varying degrees may enhance antibody
avidity, improveCD4+ T cell help, and primeCD8+ T cells through
cross-presentation. Incorporating systems biology assessments
of the earliest innate immune responses within hours to the first
week after immunization will also accelerate understanding the
key properties that lead to durable, protective B and T cell
responses (Pulendran, 2009).
Improving Vaccine Breadth with Mosaic
and Conserved Vaccine Inserts
Because of high diversity of circulating HIV-1 strains, vaccines
using sequences from reference strains might be insufficientImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 549
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topes are observed. A mosaic vaccine strategy using in silico
algorithms to recombine vaccine sequences may improve
coverage of sequences found in circulating HIV-1 strains
(Fischer et al., 2007). The first experimental studies in rhesus
macaques look encouraging and suggest that the mosaic
approach may elicit broad T cell responses in the context of
many vaccine regimens (Barouch et al., 2010; Santra et al.,
2010). Other groups have pursued designs featuring conserved
HIV-1 regions representing multiple clades (Le´tourneau et al.,
2007) and HIV-1 M group strains (Rolland et al., 2007) to
circumvent induction of responses to variable regions that
can readily escape CTL pressure. Taken together, these
approaches will have the greatest utility if they can efficiently
broaden CD4+ T cell, CD8+ T cell, and B cell responses in clin-
ical trials.
Developing Alternative Vaccine Vectors
Adenovirus-based vaccine vectors have many desirable pro-
perties, but since the Step trial results were announced there
has been concern that inclusion of subjects with Ad5-neutral-
izing antibodies prior to vaccination with an Ad5 vector could
have a negative impact on immunogenicity as well as increase
potential risk for infection, particularly among uncircumcised
males (Buchbinder et al., 2008). If these concerns are borne
out, there is a need for alternate adenovirus vectors based on
serotypes with low prevalence in target populations. Efforts
thus far have primarily focused on human adenoviruses Ad26
and Ad35 and several chimpanzee adenoviruses (reviewed in
Barouch, 2010).
Poxvirus vectors have a long successful history in the veteri-
nary field and feature many of the same potential benefits as
adenovirus-based vectors in carrying gene inserts and in
inducing T cell responses. Concentrated efforts are underway
to develop and improve several poxvirus vectors, including
ALVAC as deployed in the Thai trial, MVA, NYVAC, and fowlpox
(Pantaleo et al., 2010).
Although both adenovirus- and poxvirus-based vectors are
effective at stimulating CD4+ and CD8+ T cell responses, those
responses tend to peak rapidly and attenuate after vaccination.
An intriguing alternate strategy to maintain differentiated effector
memory T cells uses a cytomegalovirus (CMV)-based vector.
A rhesus CMV vaccine containing SIV gene inserts was able
to persistently infect rhesus macaques and maintain robust
SIV-specific CD4+ and CD8+ T cell responses. Although local
mucosal infection occurred in most vaccinated animals after
low-dose mucosal SIV challenge, protection from systemic
infection was observed for extended periods in the majority of
animals (Hansen et al., 2009). Additional studies are needed to
further assess the mechanisms of SIV protection with this or
other persistent vectors that could more rapidly arm the mucosa
with effector T cells.
Perspectives and Conclusions
The obstacles of designing an HIV-1 vaccine that can induce
protective immunity are complex and daunting. Despite nearly
three decades of searching for a vaccine, we do not know the
specific immune components sufficient to protect against
HIV-1 and we do not know how best to elicit responses that550 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.we predict will be protective. Clues from findings in nonhuman
primate SIV vaccine models and from persons who exhibit
unusual control of HIV-1 replication have not translated into
vaccine efficacy in humans. The Step trial elicited the desired
HIV-1-specific CD8+ T cells, yet the trial failed. In contrast, the
RV144 trial, which did not elicit these responses, seemed to offer
modest protection against HIV-1 acquisition, with 31% vaccine
efficacy. Moreover, it has been generally assumed that
vaccine-induced protection against HIV-1 acquisition would
require potent bnAbs, but the RV144 vaccine regimen does not
appear to have induced bnAbs despite showing a low-level
reduction in infection rates.
Where does the field go from here? For induction of protec-
tive antibodies the main research directions are to define ways
to induce bnAbs systemically and mucosally, to determine
whether any easily induced antibodies can interrupt transmis-
sion, and to understand why HIV-1 Env antibodies are short
lived in comparison to other viral envelope antibodies. The
path to induction of bnAbs will come from understanding
the B cell regulatory and tolerance pathways of anti-Env anti-
body production and from design of optimal immunogens tar-
geted at naive and memory B cell populations that can
respond to HIV-1 envelope. The path to determining correlates
of protection mediated by easily induced antibodies that act
by Fc receptor-mediated anti-HIV-1 activity or by blocking
the earliest events in transmission will come from isolating
human mAbs with various anti-HIV-1 activities (Table 2) and
testing their ability to prevent HIV-1 acquisition in passive
transfer nonhuman primate studies. The path to induction of
long-lived systemic mucosal antibodies lies in the under-
standing of, and optimizing, the B cell germinal center Env
antibody response.
For induction of protective T cells, the critical research areas
will be directed toward in-depth understanding of the functional
profiles that CD8+ T cells require to restrict early infection and
how to target these effectors to the mucosa, defining new strat-
egies to increase breadth for CD4+ and CD8+ T cell epitope
recognition, and identifying the properties of CD4+ T cells that
can simultaneously stimulate the quality and persistence of
protective CD8+ T cell and B cell responses.
Finally, over the next 5 years, the field will strive to replicate
and improve on the RV144 trial results by: (1) conducting a
detailed immune correlates analysis of the RV144 trial, (2)
completing the HVTN 505 trial evaluating the effect of a DNA-
prime Ad5-boost regimen, including multiclade env inserts, on
reducing post-infection viral set point, (3) evaluating the utility
of mosaic vaccines designed to elicit increased T and B cell
breadth, (4) defining effects of new adjuvant formulations on
innate, T and B cell responses, (5) conducting immunogenicity
comparative studies on the effectiveness of alternate serotype
adenovirus and novel pox vectors for eliciting improved quality
and breadth of T cell and antibody responses, and (6) conducting
detailed study into the biology of vaccine induction of protective
responses targeting mucosal anti-HIV-1 immune responses.
Coordination between nonhuman primate vaccine challenge
studies and human vaccine clinical trials will be essential to
advance new vaccine concepts into the product development
pipeline and to accelerate the pace of initiating future HIV-1
vaccine efficacy trials.
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